Sulzer Medica launches biological implant in Europe:
This article was originally published in Clinica
Executive Summary
Sulzer Medica has launched its first biological implant, the collagen meniscus implant, CMI, in Europe. The product is a sponge-like structure of highly purified collagen. The porous structure of the CMI serves as a scaffold to support ingrowth of cells and the formation of new meniscus tissue. The product was developed jointly with Redwood, California-based ReGen Biologics, in which Sulzer has a minority holding. Sulzer, of Winterthur, Switzerland, has marketing and distribution rights to the product worldwide, excluding the US.